Literature DB >> 33326093

(Immuno)histological Analysis of Ewing Sarcoma.

David Marcilla1, Isidro Machado2,3, Thomas G P Grünewald4, Antonio Llombart-Bosch5, Enrique de Álava6,7.   

Abstract

The diagnosis of Ewing sarcoma requires the integration of the information generated from numerous techniques, some of them being very sophisticated. However, the first steps of the diagnostic process are crucial to achieve the maximum possible diagnostic performance. In this chapter we will review how to handle the diagnostic specimen from its collection, how to prepare it for diagnosis, how to make a complete pathology report, and provide guidance for the reasonable use of immunohistochemical techniques in this malignancy.

Entities:  

Keywords:  Decalcification; Diagnostic report; Differential diagnosis; Ewing sarcoma; Immunohistochemistry; Neoadjuvant therapy; Sarcoma

Mesh:

Substances:

Year:  2021        PMID: 33326093     DOI: 10.1007/978-1-0716-1020-6_5

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  3 in total

Review 1.  [Protocol for the study of bone tumours and standardization of pathology reports].

Authors:  Isidro Machado; José Juan Pozo; David Marcilla; Julia Cruz; Juan C Tardío; Aurora Astudillo; Sílvia Bagué
Journal:  Rev Esp Patol       Date:  2016-10-20

2.  Morphologic and immunophenotypic diversity in Ewing family tumors: a study of 66 genetically confirmed cases.

Authors:  Andrew L Folpe; John R Goldblum; Brian P Rubin; Bahig M Shehata; Wendy Liu; Angelo P Dei Tos; Sharon W Weiss
Journal:  Am J Surg Pathol       Date:  2005-08       Impact factor: 6.394

3.  BCOR-CCNB3 Fusion Positive Sarcomas: A Clinicopathologic and Molecular Analysis of 36 Cases With Comparison to Morphologic Spectrum and Clinical Behavior of Other Round Cell Sarcomas.

Authors:  Yu-Chien Kao; Adepitan A Owosho; Yun-Shao Sung; Lei Zhang; Yumi Fujisawa; Jen-Chieh Lee; Leonard Wexler; Pedram Argani; David Swanson; Brendan C Dickson; Christopher D M Fletcher; Cristina R Antonescu
Journal:  Am J Surg Pathol       Date:  2018-05       Impact factor: 6.394

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.